Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
BMC Endocrine Disorders|December 19, 2025
The role of periodontitis as a modifier of diabetes mellitus in older patients with atrial fibrillationTakahiro Kamihara, Yuiko Yokoyama, Junya Nakamura, et al.Bioorganic & Medicinal Chemistry|May 10, 2026
Identification of non-hydroxamate histone deacetylase 8 inhibitors using deep learning-based screening of two-dimensional molecular imagesYasunobu Yamashita, Juhyun Yun, Ayumu Asai, et al.Platelets|April 10, 2015
Measurement of soluble C-type lectin-like receptor 2 in human plasmaFuminori Kazama, Junya Nakamura, Makoto Osada, et al.International Journal of Oncology|February 23, 2008
Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumorsNaoya Tatsumi, Yusuke Oji, Naoko Tsuji, et al.International Journal of Hematology|June 6, 2019
Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVIOsamu Inoue, Makoto Osada, Junya Nakamura, et al.International Journal of Oncology|April 11, 2009
Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycleJunya Nakamura, Sayaka Aoyagi, Isamu Nanchi, et al.International Journal of Cancer|April 23, 2009
WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factorYusuke Oji, Yayoi Kitamura, Eriko Kamino, et al.Therapeutic Advances in Medical Oncology|August 4, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, et al.Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.Therapeutic Advances in Medical Oncology|March 15, 2021
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, et al.Pageof 6